BTX BioTime Inc.

-0.02  -2%
Previous Close 0.94
Open 0.94
Price To Book 0.68
Market Cap 116527593
Shares 126,964,037
Volume 304,536
Short Ratio 13.87
Av. Daily Volume 645,618

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal trial data released June 14, 2017 - primary endpoint met.
Restoring normal skin contours in for patients with HIV
Phase 1/2 12-month data from cohorts 3 and 4 released July 31, 2018 with 12-mth data from all cohorts due 1Q 2019.
Cervical spinal cord injury
Interim readout 2018 October 2018.
Dry age-related macular degeneration (AMD)
Phase 2b planned for 2018.
Maintenance of relapse-free-survival in acute myeloid leukemia (AML)

Latest News

  1. AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
  2. BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD
  3. BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
  4. BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019
  5. AgeX Therapeutics to Present at Biotech Showcase 2019
  6. BioTime, Inc. (BTX): Are Hedge Funds Right About This Stock?
  7. BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke
  8. AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference
  9. BioTime to Present at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018
  10. AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American
  11. BioTime Announces Distribution of AgeX Therapeutics Shares
  12. Asterias Biotherapeutics Reports Third Quarter Results
  13. Edited Transcript of BTX earnings conference call or presentation 8-Nov-18 1:30pm GMT
  14. What Kind Of Shareholder Owns Most BioTime Inc (NYSEMKT:BTX) Stock?
  15. BioTime: 3Q Earnings Snapshot
  16. BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company
  17. BioTime Reports Third Quarter 2018 Financial Results and Provides Business Update
  18. BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call